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Background: Type 2 diabetes mellitus (T2DM) is associated with low-grade inflammation and with an increased cardiovascular risk. Unusual 
T-cells, CD4+CD28null, are expanded and associated with recurrence of acute coronary syndrome (ACS) in patients with unstable angina.
We hypothesized that CD4+CD28null cell expansion may be associated with the occurrence of cardiovascular events in T2DM subjects.
Design and Methods: Peripheral blood T cells from 60 subjects with T2DM, with no clinical evidence of cardiovascular disease, were analyzed for 
the distribution of T cell subsets by flow cytometry. High sensitivity C-reactive protein (CRP), glyco-haemoglobin A1c (HbA1c) and lipid status were 
also assessed. At 36 months of follow-up, we recorded the incidence of cardiovascular events (ACS, ictus or limb ischemia) in these subjects.
Results: CD4+CD28null cell frequency, 3.1% (range 0.3-22), in T2DM subjects was significantly higher than normal value (< 1%). At multivariate 
analysis the only independent predictor of CD4+CD28null T-cells was HbA1c (P = 0.027). At clinical follow-up, 11/60 (18.3%) subjects with T2DM 
developed a cardiovascular event. In these subjects, the frequency of CD4+CD28null T-cells was significant higher than among those without 
occurrence of cardiovascular events (p=0.01). In T2DM, the 36 months incidence of cardiovascular events was significantly higher in subjects with 
a percentage of CD4+CD28null T cells > 4% and > 10% than in those with CD4+CD28null T cells < 4% and < 10%, as assessed by the log rank test 
(respectively, p = 0.04 and p= 0.001). At Cox regression analysis, CD4+CD28null T-cell frequency was the only independent predictor of incidence of 
cardiovascular events at 36 months of follow-up (HR: 1.15; 95% CI: 1.06-1.24; P < 0.001).
Conclusions: CD4+CD28null T-cells are expanded in T2DM subjects, without clinical evidence of cardiovascular disease, and are associated with 
poor glycemic control. Moreover, this unusual T-cell population is strongly associated with the occurrence of cardiovascular events in T2DM subjects. 
Further studies will be needed to evaluate the mechanistic role of these cells in the pathogenesis of cardiovascular complications in T2DM.
